Humana's ($HUM) ACCE composite score dropped 14 points, moving from 56 to 42 out of 100. That's a meaningful single-step decline — the kind that typically reflects deterioration across more than one subscore rather than a single isolated data point.
The current score breakdown: Growth sits at 52, Value at 35, and Quality at 40. None of those are strong readings, and the Value score in particular is doing heavy lifting in pulling the composite lower.
What it means
A 14-point drop in the composite usually traces back to one or more of the following:
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
Valuation pressure. The Value subscore of 35 is the weakest of the three, and it's easy to see why. $HUM trades at a trailing P/E of 41.0 and a forward P/E of 42.2 — elevated multiples for a healthcare insurer. The ACCE 6-model fair value estimate sits at $309.33, which implies the stock is trading roughly 17.8% above what the models consider fair. The analyst consensus target of $304.33 tells a similar story. When a stock runs well ahead of modeled fair value, the Value subscore takes the hit.
Earnings quality vs. earnings growth. Revenue grew 23.5% year over year — that's the number propping up the Growth subscore of 52. But earnings fell 4.6% over the same period. Revenue expanding while earnings contract is a margin compression signal, and it shows up directly in the Quality subscore. Net margin is just 0.8%, and ROE is 6.3% — thin figures for a company trading at these multiples. FCF yield also sits at 0.8%, which limits the cushion the Quality score can draw on even with an "earnings quality: strong" label.
Momentum math. $HUM is up 56.8% over the past year. Strong price momentum can actually work against a composite score when it outruns fundamental improvement — the stock gets more expensive relative to fair value, which feeds back into the Value subscore and can drag the composite down even as the share price climbs.
What to watch. The tension here is straightforward: revenue growth is real, but profitability is not keeping pace. A 0.9% dividend yield offers minimal income support at this price level. Until margin trends improve or the stock reprices closer to the $309-$304 fair value range, the Value and Quality subscores have limited room to recover.
For the current price and live score updates, see acceinvestments.com/stocks/HUM.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
